Chenodeoxycholic acid

Generic Medicine Info
Should be taken with food.
Non-visualising gallbladder after two successive single doses of dye. Radiopaque stones. Gallstone complications or reasons necessitating gallbladder surgery (e.g. unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula). Hepatic impairment, hepatocyte dysfunction or bile ductal abnormalities (e.g. intrahepatic cholestasis, primary biliary cirrhosis, sclerosing cholangitis). Pregnancy.
Special Precautions
Lactation. Monitoring Parameters Monitor serum aminotransferase monthly for first 3 months, then every 3 months thereafter during therapy; serum cholesterol every 6 months; oral cholecystograms and ultrasonograms at 6-9 month intervals. Confirm stone dissolution after 1-3 months of treatment.
Adverse Reactions
Significant: Diarrhoea, hepatotoxicity, colon cancer, gallstone recurrence. Blood and lymphatic system disorders: Leucopenia. Investigations: Increased serum transaminases, increased LDL and total serum cholesterol. Gastrointestinal disorders: Nausea, vomiting, biliary colic, abdominal cramps, abdominal pain, anorexia, constipation, dyspepsia, flatulence.
Drug Interactions
Decreased absorption with bile acid sequestrants (e.g. cholestyramine, colestipol) and aluminium-containing antacids. Increased biliary cholesterol secretion and reduced efficacy with fibric acid derivatives (e.g. clofibrate) and oestrogen derivatives. May increase the anticoagulant effect of vitamin K antagonists (e.g. warfarin).
CIMS Class
Cholagogues, Cholelitholytics & Hepatic Protectors
ATC Classification
A05AA01 - chenodeoxycholic acid ; Belongs to the class of bile acids. Used in bile therapy.
Disclaimer: This information is independently developed by CIMS based on chenodeoxycholic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in